ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ARIA Ariad Pharmaceuticals, Inc.

23.99
0.00 (0.00%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Ariad Pharmaceuticals, Inc. NASDAQ:ARIA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 23.99 23.80 22.88 0 01:00:00

ARIAD to Present at the Goldman Sachs Annual Global Healthcare Conference

08/06/2015 12:35pm

Business Wire


Ariad (NASDAQ:ARIA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Ariad Charts.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Goldman Sachs Annual Global Healthcare Conference being held in Rancho Palos Verdes, CA. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Wednesday, June 10, at 11:20 a.m. (PT).

The ARIAD presentation at the Goldman Sachs Annual Global Healthcare Conference will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay of the presentation will also be available and archived on the site for three weeks.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

ARIAD Pharmaceuticals, Inc.For InvestorsKendra Adams, 617-503-7028Kendra.adams@ariad.com

orFor MediaLiza Heapes, 617-621-2315Liza.heapes@ariad.com

1 Year Ariad Chart

1 Year Ariad Chart

1 Month Ariad Chart

1 Month Ariad Chart

Your Recent History

Delayed Upgrade Clock